SALO, Finland - Tuesday, October 1st 2013 [ME NewsWire]
(BUSINESS WIRE)-- SATEL is a leading manufacturer of radio modems, which recently released a new data transceiver module SATELLINE-M3-TR3. The module is specifically designed to be integrated into host devices. It is compact, slim and easy to add to various systems. This makes it a versatile and exceptionally compatible solution for data transfer.
With a 70 MHz tuning range, selectable channel width and 128-bit encryption available for secure transmission, it makes this one of the most versatile SATEL products available. With a weight of 18 grams and compatibility with many other manufacturers’ radio protocols it makes this module a simple choice. It utilizes Intelligent Power Save, which is a feature enabling very low power consumption.
SATELLINE-M3-TR3 is very flexible and can be customised using numerous ways. For example the shape of the PCB and mechanical fasteners can be customised as well as the interfaces and antenna connector. The module meets the FCC narrow banding requirements and complies with EN 300 113-2 Annex A, EN 301 489-1, -5, EN 60950-1 and FCC CFR47 standards.
Radio modems communicate wirelessly with each other across a range of up to tens of kilometers. Radio modems are available for both unlicensed and licensed frequency bands. Radio modems are utilized for example in SCADA, factory automation, GNSS, traffic control, security and telemetry applications. All SATEL radio modems fulfill the RoHS requirements. They are designed and manufactured in Finland.
SATEL is a wireless data communication specialist and one of the leading radio modem suppliers in the world. SATEL is an ISO certified company and has been specializing in designing and manufacturing radio modems for almost 30 years. The company’s headquarters is in Finland and the distributor network covers over 100 countries worldwide. For additional information, visit www.satel.com.
Product pictures:
http://www.satel.com/downloads/product-images
More information:
http://www.satel.com/products/radio-modems/customer-specific-radio-modems
Contacts
SATEL
CEO Pekka Aura
Telephone: +358 2 777 7800
E-mail: info@satel.com
www: www.satel.com
Permalink: http://www.me-newswire.net/news/8669/en
Wednesday, October 2, 2013
Tuesday, October 1, 2013
ASTRA 2E Satellite Launched Successfully
54th SES satellite to be deployed into 28.2/28.5 degrees East orbital arc
BAIKONUR & LUXEMBOURG - Monday, September 30th 2013 [ME NewsWire]
(BUSINESS WIRE) SES S.A. (NYSE Paris:SESG) (LuxX:SESG) is pleased to announce that the ASTRA 2E satellite roared into space on board an ILS Proton Breeze M booster last night at 3:38 am Baikonur time (23:38 CET and 17:38 EDT on September 29). After a 9-hour, 12-minute mission, the Breeze M upper stage of the Proton rocket successfully released the ASTRA 2E satellite directly into geostationary transfer orbit.
ASTRA 2E will be deployed at the 28.2/28.5 degrees orbital arc. The satellite was built for SES by Astrium of France. Based on the highly reliable Eurostar E3000 platform, the spacecraft carries 60 Ku-band transponders, including 12 incremental transponders for delivery of services outside Europe, as well as 4 Ka-band transponders. It will enable the delivery of next generation broadcast and broadband services in Europe, the Middle East and Africa. ASTRA 2E, which had a launch mass of 6 tonnes, will feature a wingspan of 40m once its solar arrays are deployed in orbit, generating 13 kW of spacecraft power at the end of its 15-year design lifetime.
“We would like to thank Astrium and ILS for the successful ASTRA 2E mission. The 54th satellite in SES’ global fleet provides significant capacity expansion at a strategic orbital neighborhood over Europe. In combination with ASTRA 2F which was launched in September 2012, and the upcoming ASTRA 2G due for launch next year, ASTRA 2E is an important part of our fleet renewal programme at the 28.2/28.5 degrees orbital arc. The state-of-the-art new satellites provide more focused and higher power to our broadcast customers, while the Ka-band on board supports the delivery of next-generation satellite broadband services”, stated Romain Bausch, President and CEO of SES.
Note to Editors:
The next SES launch is scheduled for October 2013, when a SpaceX Falcon 9 booster will orbit the SES-8 spacecraft, manufactured by Orbital, from Cape Canaveral, Florida.
Follow SES on:
Twitter: https://twitter.com/SES_Satellites
Facebook: https://www.facebook.com/SES.YourSatelliteCompany
YouTube: http://www.youtube.com/SESVideoChannel
Blog: http://en.ses.com/4243715/blog
About SES
SES is a world-leading satellite operator with a fleet of 54 geostationary satellites. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators and business and governmental organisations worldwide.
SES stands for long-lasting business relationships, high-quality service and excellence in the broadcasting industry. The culturally diverse regional teams of SES are located around the globe and work closely with customers to meet their specific satellite bandwidth and service requirements.
SES (NYSE Paris:SESG) (LuxX:SESG) holds participations in Ciel in Canada and QuetzSat in Mexico, as well as a strategic participation in satellite infrastructure start-up O3b Networks. Further information under: www.ses.com.
Contacts
SES
Yves Feltes
Media Relations
+352 710 725 311
Yves.Feltes@ses.com
Permalink: http://www.me-newswire.net/news/8662/en
BAIKONUR & LUXEMBOURG - Monday, September 30th 2013 [ME NewsWire]
(BUSINESS WIRE) SES S.A. (NYSE Paris:SESG) (LuxX:SESG) is pleased to announce that the ASTRA 2E satellite roared into space on board an ILS Proton Breeze M booster last night at 3:38 am Baikonur time (23:38 CET and 17:38 EDT on September 29). After a 9-hour, 12-minute mission, the Breeze M upper stage of the Proton rocket successfully released the ASTRA 2E satellite directly into geostationary transfer orbit.
ASTRA 2E will be deployed at the 28.2/28.5 degrees orbital arc. The satellite was built for SES by Astrium of France. Based on the highly reliable Eurostar E3000 platform, the spacecraft carries 60 Ku-band transponders, including 12 incremental transponders for delivery of services outside Europe, as well as 4 Ka-band transponders. It will enable the delivery of next generation broadcast and broadband services in Europe, the Middle East and Africa. ASTRA 2E, which had a launch mass of 6 tonnes, will feature a wingspan of 40m once its solar arrays are deployed in orbit, generating 13 kW of spacecraft power at the end of its 15-year design lifetime.
“We would like to thank Astrium and ILS for the successful ASTRA 2E mission. The 54th satellite in SES’ global fleet provides significant capacity expansion at a strategic orbital neighborhood over Europe. In combination with ASTRA 2F which was launched in September 2012, and the upcoming ASTRA 2G due for launch next year, ASTRA 2E is an important part of our fleet renewal programme at the 28.2/28.5 degrees orbital arc. The state-of-the-art new satellites provide more focused and higher power to our broadcast customers, while the Ka-band on board supports the delivery of next-generation satellite broadband services”, stated Romain Bausch, President and CEO of SES.
Note to Editors:
The next SES launch is scheduled for October 2013, when a SpaceX Falcon 9 booster will orbit the SES-8 spacecraft, manufactured by Orbital, from Cape Canaveral, Florida.
Follow SES on:
Twitter: https://twitter.com/SES_Satellites
Facebook: https://www.facebook.com/SES.YourSatelliteCompany
YouTube: http://www.youtube.com/SESVideoChannel
Blog: http://en.ses.com/4243715/blog
About SES
SES is a world-leading satellite operator with a fleet of 54 geostationary satellites. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators and business and governmental organisations worldwide.
SES stands for long-lasting business relationships, high-quality service and excellence in the broadcasting industry. The culturally diverse regional teams of SES are located around the globe and work closely with customers to meet their specific satellite bandwidth and service requirements.
SES (NYSE Paris:SESG) (LuxX:SESG) holds participations in Ciel in Canada and QuetzSat in Mexico, as well as a strategic participation in satellite infrastructure start-up O3b Networks. Further information under: www.ses.com.
Contacts
SES
Yves Feltes
Media Relations
+352 710 725 311
Yves.Feltes@ses.com
Permalink: http://www.me-newswire.net/news/8662/en
PMI Acquires Human Systems International, a UK-based Assessment and Benchmarking Firm
HSI and PMI formalize longstanding partnership to deliver unparalleled strategic business insight
LONDON - Monday, September 30th 2013 [ME NewsWire]
(BUSINESS WIRE)-- The Project Management Institute (PMI) has acquired Human Systems International (HSI), a UK-based assessment and benchmarking company with keen organizational insight developed over 20 years of collecting best practice project, program and portfolio management data from commercial and government organizations around the world.
“HSI and PMI are like-minded organizations, focused on providing thought leadership, knowledge and networking opportunities designed to improve company and practitioner capabilities in project, program and portfolio management,” said Mark A. Langley, President and CEO of PMI.
Over the past two decades, HSI has developed the world’s largest and most robust database that highlights organizational project and program management best practices. The insights assembled from this rich data source will accelerate PMI’s ability to develop relevant and credible thought leadership positions, content resources, and knowledge sharing among members and other key stakeholders. PMI believes this acquisition will further enable advancement of the project management profession and raise awareness of the value that project, program and portfolio management (PPPM) can deliver as strategic business drivers.
“HSI’s assessment and benchmarking tools integrate well into PMI’s value delivery plans for business and government. The real strategic value of combining the two organizations comes from integrating HSI’s data-driven perspective on project, program and portfolio management best practices, with PMI’s global reach, to deliver business insight that has been previously unavailable,” said Deanna Landers, Chair of PMI’s Board of Directors.
“PMI’s acquisition of Human Systems brings together two driving forces of thought leadership within the project management industry. PMI has a history of robust research in the area of project, program and portfolio management, which provides a cultural fit with Human Systems benchmarking and analysis for PPPM improvement initiatives,” said Terry Cooke-Davies, Group Chairman of Human Systems International.
Post-acquisition, HSI’s benchmarking approach will remain methodology-independent and standards-agnostic, focusing on the best practices that have emerged over two decades of data collection from multinational organizations.
About Human Systems International (HSI)
Human Systems International (HSI), is a leading assessment and benchmarking company with offices in London and Sydney, and operations throughout Europe and Asia-Pacific. HSI offers a wide range of diagnostic and analytic tools for improving organization project management capabilities, including the 4Q Assessment Model, which is used by organizations across all industry sectors as well as government agencies. Over the past two decades, HSI has developed the world’s largest and most robust database highlighting organizational project and program management best practices.
About Project Management Institute (PMI)
PMI is the one of the world's largest not-for-profit membership association for the project management profession. Our professional resources and research empower more than 700,000 members, credential holders and volunteers in nearly every country in the world to enhance their careers, improve their organizations' success and further mature the profession. PMI's worldwide advocacy for project management is reinforced by our globally recognized standards and certification programs, extensive academic and market research programs, chapters and communities of practice, and professional development opportunities.
Visit us at www.PMI.org, www.facebook.com/PMInstitute and on Twitter @PMInstitute.
Contacts
PMI
Megan Maguire Kelly, +1 610-356-4600 ext. 7030
Megan.Kelly@PMI.org
Permalink: http://www.me-newswire.net/news/8668/en
LONDON - Monday, September 30th 2013 [ME NewsWire]
(BUSINESS WIRE)-- The Project Management Institute (PMI) has acquired Human Systems International (HSI), a UK-based assessment and benchmarking company with keen organizational insight developed over 20 years of collecting best practice project, program and portfolio management data from commercial and government organizations around the world.
“HSI and PMI are like-minded organizations, focused on providing thought leadership, knowledge and networking opportunities designed to improve company and practitioner capabilities in project, program and portfolio management,” said Mark A. Langley, President and CEO of PMI.
Over the past two decades, HSI has developed the world’s largest and most robust database that highlights organizational project and program management best practices. The insights assembled from this rich data source will accelerate PMI’s ability to develop relevant and credible thought leadership positions, content resources, and knowledge sharing among members and other key stakeholders. PMI believes this acquisition will further enable advancement of the project management profession and raise awareness of the value that project, program and portfolio management (PPPM) can deliver as strategic business drivers.
“HSI’s assessment and benchmarking tools integrate well into PMI’s value delivery plans for business and government. The real strategic value of combining the two organizations comes from integrating HSI’s data-driven perspective on project, program and portfolio management best practices, with PMI’s global reach, to deliver business insight that has been previously unavailable,” said Deanna Landers, Chair of PMI’s Board of Directors.
“PMI’s acquisition of Human Systems brings together two driving forces of thought leadership within the project management industry. PMI has a history of robust research in the area of project, program and portfolio management, which provides a cultural fit with Human Systems benchmarking and analysis for PPPM improvement initiatives,” said Terry Cooke-Davies, Group Chairman of Human Systems International.
Post-acquisition, HSI’s benchmarking approach will remain methodology-independent and standards-agnostic, focusing on the best practices that have emerged over two decades of data collection from multinational organizations.
About Human Systems International (HSI)
Human Systems International (HSI), is a leading assessment and benchmarking company with offices in London and Sydney, and operations throughout Europe and Asia-Pacific. HSI offers a wide range of diagnostic and analytic tools for improving organization project management capabilities, including the 4Q Assessment Model, which is used by organizations across all industry sectors as well as government agencies. Over the past two decades, HSI has developed the world’s largest and most robust database highlighting organizational project and program management best practices.
About Project Management Institute (PMI)
PMI is the one of the world's largest not-for-profit membership association for the project management profession. Our professional resources and research empower more than 700,000 members, credential holders and volunteers in nearly every country in the world to enhance their careers, improve their organizations' success and further mature the profession. PMI's worldwide advocacy for project management is reinforced by our globally recognized standards and certification programs, extensive academic and market research programs, chapters and communities of practice, and professional development opportunities.
Visit us at www.PMI.org, www.facebook.com/PMInstitute and on Twitter @PMInstitute.
Contacts
PMI
Megan Maguire Kelly, +1 610-356-4600 ext. 7030
Megan.Kelly@PMI.org
Permalink: http://www.me-newswire.net/news/8668/en
DTCC to Partner with Global Banks to Develop Comprehensive Client Reference Data Service
ME Newswire / Business Wire
LONDON & NEW YORK - Monday, September 30th 2013
The Depository Trust & Clearing Corporation (DTCC) announced today that it has signed a memorandum of understanding (MOU) with a group of large global banks that includes Barclays, Credit Suisse, Goldman Sachs and JPMorgan Chase and others to jointly develop a comprehensive service to collect and manage client entity reference data necessary to meet regulatory requirements and other normal course of business activities.
The parties to the MOU expect to have a state-of-the-art client data and documentation platform leveraging significant design work already undertaken in partnership with a broad group of major sell-side and buy-side firms globally. More immediate interim releases will be provided to address specific regulatory needs. Over time, the service will address client reference data requirements of banks and broker dealers, as well as asset managers and hedge funds, including, among other items, legal entity hierarchies, standing settlement instructions (SSIs), regulatory compliance data (Dodd-Frank, EMIR, etc.), client on-boarding/KYC, Tax/FATCA and other requirements.
“Our ultimate aim is to support the industry’s call for a comprehensive, centralized platform to effectively manage virtually all client reference data,” said Michael C. Bodson, DTCC President and Chief Executive Officer. “We are very pleased that we now have an MOU with a group of the industry’s top multinational participants. With their partnership, and the support of our Board of Directors, we are moving forward aggressively to bring this solution to market.”
In addition, by developing standardized processes and data formats in cooperation with market participants and the regulatory community, the parties to the MOU aim to effect substantial improvements in the control environment surrounding client onboarding and to streamline supervisory examination of these processes.
The service will benefit from DTCC’s broad experience in implementing extensible and scalable data platforms and operational processes, and will build upon its current and growing suite of industry-owned reference data assets, which includes Avox, its leading data validation operation that maintains cleansed publicly-available reference data for the service, and Omgeo ALERT, a standing settlement instruction database that contains the majority of the standing settlement instructions used by both buy- and sell-side market participants today.
“We are very excited to be a part of this joint initiative. Client service is of utmost importance to Credit Suisse, and the enhanced client reference data resulting from this service offering will assist us in meeting client needs,” said Colin Hall, Credit Suisse Chief Data Officer, Investment Banking. “We firmly believe that our collaboration with the DTCC and other peer firms has the opportunity to deliver significant benefits to the broader market from control, regulatory and client service perspectives."
Notes to the Editor: On September 17, Omgeo issued a press release announcing its partnership with DTCC and the industry to develop with ALERT as its foundation, a global, industry-governed hub to store and communicate the “golden copy” of Standing Settlement Instructions (SSIs) for all products and geographies for the financial services industry – another important component of this global client reference data utility.
About DTCC
DTCC has operating facilities and data centers around the world and, through its subsidiaries, automates, centralizes, and standardizes the post-trade processing of financial transactions for thousands of institutions worldwide. With 40 years of experience, DTCC is the premier post-trade market infrastructure for the global financial services industry, simplifying the complexities of clearance, settlement, asset servicing, global data management and information services for equities, corporate and municipal bonds, government and mortgage-backed securities, derivatives, money market instruments, syndicated loans, mutual funds, alternative investment products, and insurance transactions. In 2012, DTCC’s subsidiaries processed securities transactions valued at approximately US$1.6 quadrillion. Its depository provides custody and asset servicing for securities issues from 131 countries and territories valued at US$37.2 trillion. DTCC’s global trade repositories record more than US$500 trillion in gross notional value of transactions made worldwide.
For more information, visit dtcc.com, and follow us on Twitter: http://twitter.com/The_DTCC.
Contacts
Depository Trust & Clearing Corporation
Judy Inosanto, 212-855-5424
jinosanto@dtcc.com
Melissa Rowling, 020 7324 5490
melissa.rowling@greentarget.co.uk
Permalink: http://www.me-newswire.net/news/8660/en
LONDON & NEW YORK - Monday, September 30th 2013
The Depository Trust & Clearing Corporation (DTCC) announced today that it has signed a memorandum of understanding (MOU) with a group of large global banks that includes Barclays, Credit Suisse, Goldman Sachs and JPMorgan Chase and others to jointly develop a comprehensive service to collect and manage client entity reference data necessary to meet regulatory requirements and other normal course of business activities.
The parties to the MOU expect to have a state-of-the-art client data and documentation platform leveraging significant design work already undertaken in partnership with a broad group of major sell-side and buy-side firms globally. More immediate interim releases will be provided to address specific regulatory needs. Over time, the service will address client reference data requirements of banks and broker dealers, as well as asset managers and hedge funds, including, among other items, legal entity hierarchies, standing settlement instructions (SSIs), regulatory compliance data (Dodd-Frank, EMIR, etc.), client on-boarding/KYC, Tax/FATCA and other requirements.
“Our ultimate aim is to support the industry’s call for a comprehensive, centralized platform to effectively manage virtually all client reference data,” said Michael C. Bodson, DTCC President and Chief Executive Officer. “We are very pleased that we now have an MOU with a group of the industry’s top multinational participants. With their partnership, and the support of our Board of Directors, we are moving forward aggressively to bring this solution to market.”
In addition, by developing standardized processes and data formats in cooperation with market participants and the regulatory community, the parties to the MOU aim to effect substantial improvements in the control environment surrounding client onboarding and to streamline supervisory examination of these processes.
The service will benefit from DTCC’s broad experience in implementing extensible and scalable data platforms and operational processes, and will build upon its current and growing suite of industry-owned reference data assets, which includes Avox, its leading data validation operation that maintains cleansed publicly-available reference data for the service, and Omgeo ALERT, a standing settlement instruction database that contains the majority of the standing settlement instructions used by both buy- and sell-side market participants today.
“We are very excited to be a part of this joint initiative. Client service is of utmost importance to Credit Suisse, and the enhanced client reference data resulting from this service offering will assist us in meeting client needs,” said Colin Hall, Credit Suisse Chief Data Officer, Investment Banking. “We firmly believe that our collaboration with the DTCC and other peer firms has the opportunity to deliver significant benefits to the broader market from control, regulatory and client service perspectives."
Notes to the Editor: On September 17, Omgeo issued a press release announcing its partnership with DTCC and the industry to develop with ALERT as its foundation, a global, industry-governed hub to store and communicate the “golden copy” of Standing Settlement Instructions (SSIs) for all products and geographies for the financial services industry – another important component of this global client reference data utility.
About DTCC
DTCC has operating facilities and data centers around the world and, through its subsidiaries, automates, centralizes, and standardizes the post-trade processing of financial transactions for thousands of institutions worldwide. With 40 years of experience, DTCC is the premier post-trade market infrastructure for the global financial services industry, simplifying the complexities of clearance, settlement, asset servicing, global data management and information services for equities, corporate and municipal bonds, government and mortgage-backed securities, derivatives, money market instruments, syndicated loans, mutual funds, alternative investment products, and insurance transactions. In 2012, DTCC’s subsidiaries processed securities transactions valued at approximately US$1.6 quadrillion. Its depository provides custody and asset servicing for securities issues from 131 countries and territories valued at US$37.2 trillion. DTCC’s global trade repositories record more than US$500 trillion in gross notional value of transactions made worldwide.
For more information, visit dtcc.com, and follow us on Twitter: http://twitter.com/The_DTCC.
Contacts
Depository Trust & Clearing Corporation
Judy Inosanto, 212-855-5424
jinosanto@dtcc.com
Melissa Rowling, 020 7324 5490
melissa.rowling@greentarget.co.uk
Permalink: http://www.me-newswire.net/news/8660/en
KCI, LifeCell and Systagenix to Form One Company Focused on Transformational Healing Solutions under the Leadership of President & CEO Joe Woody
SAN ANTONIO - Monday, September 30th 2013 [ME NewsWire]
(BUSINESS WIRE) The Board of Directors of the parent company of Kinetic Concepts, Inc. (KCI) and LifeCell Corporation (LifeCell) announced today that KCI, LifeCell and Systagenix will form one globally diversified wound care, biologics and regenerative medicine company under the leadership of President & CEO Joe Woody. Phil Croxford, the current commercial operations leader at LifeCell, has been appointed Senior Vice President and the permanent leader of LifeCell.
The combined company will be the global leader in transformational healing solutions, devoted to advancing the science of healing with superior products, innovative therapies and cost effective solutions that speed healing, reduce complications and improve patient lives. Each of the businesses will execute on this unified vision by leveraging shared competencies, portfolio expertise and existing sales channels.
As one of the top global medical technology companies, the combined company will remain the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair and a market leader in advanced wound care. KCI, LifeCell and Systagenix will be poised for future success as a strategically diversified global company, with established commercial scale and a world-class wound care and biologics portfolio.
“The combination of these businesses will form a leading medical technology company with over $2 billion in revenue and a very important position within the healthcare system,” said Buddy Gumina, chairman of the Board of Directors of the parent company of KCI and LifeCell. “The new company, under the proven leadership of Joe Woody, will amplify existing capabilities, open the door for new growth opportunities and improve the lives of patients around the world.”
“Operating as one company will foster collaboration and increased innovation across platforms, leading to exciting new products that will address unmet clinical needs,” said Joe Woody, president & CEO. “The combination of KCI, LifeCell and Systagenix will allow us to strengthen our customer relationships, while creating opportunities to cross-sell our products across the entire continuum of care – following the patient from the operating room to the home with a combined portfolio of best-in-class products and therapies.”
KCI and LifeCell will begin operating as one company immediately under the leadership of President & CEO Joe Woody. Systagenix will be integrated into the combined company upon closing of KCI’s acquisition of Systagenix, which is expected to occur in the fourth quarter of 2013.
About KCI
KCI is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively impacting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.
About LifeCell
LifeCell Corporation, based in Bridgewater, NJ, is a leader in regenerative medicine, develops and markets innovative tissue repair products for the reconstructive, orthopedic and urogynecologic biosurgery markets. LifeCell™ products include Strattice™ Reconstructive Tissue Matrix and AlloDerm® Regenerative Tissue Matrix for plastic, reconstructive, and general surgical applications; Cymetra® Regenerative Tissue Matrix, a particulate form of AlloDerm® Tissue Matrix suitable for injection; Repliform® Regenerative Tissue Matrix for urogynecologic surgical procedures; Graftjacket® and Conexa™ for orthopedic surgical procedures; and the SPY® Elite System for the visualization and evaluation of tissue perfusion. Additional information about LifeCell and its products is available at www.LifeCell.com.
About Systagenix
Systagenix is a global leader in innovative wound care established in 2008 following the acquisition of Johnson & Johnson’s professional wound care business by One Equity Partners. Systagenix is 100% dedicated to wound care, developing and marketing advanced wound diagnostic and therapeutic solutions and supplying over 20 million advanced wound dressings per month globally. Systagenix’ longstanding commitment to skin and wound care began with innovative wound care treatments developed by the experienced team of R&D Scientists at the Gargrave Centre of Excellence for Wound Healing in North Yorkshire, England. With approximately 800 employees worldwide, Systagenix distributes products and services to more than 100 countries.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130930005524/en/
Contacts
KCI Corporate Communications
Mike Barger, +1-210-255-6824
mike.barger@kci1.com
KCI Investor Relations
Nathan Speicher, +1-210-255-6027
nathan.speicher@kci1.com
Permalink: http://www.me-newswire.net/news/8656/en
(BUSINESS WIRE) The Board of Directors of the parent company of Kinetic Concepts, Inc. (KCI) and LifeCell Corporation (LifeCell) announced today that KCI, LifeCell and Systagenix will form one globally diversified wound care, biologics and regenerative medicine company under the leadership of President & CEO Joe Woody. Phil Croxford, the current commercial operations leader at LifeCell, has been appointed Senior Vice President and the permanent leader of LifeCell.
The combined company will be the global leader in transformational healing solutions, devoted to advancing the science of healing with superior products, innovative therapies and cost effective solutions that speed healing, reduce complications and improve patient lives. Each of the businesses will execute on this unified vision by leveraging shared competencies, portfolio expertise and existing sales channels.
As one of the top global medical technology companies, the combined company will remain the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair and a market leader in advanced wound care. KCI, LifeCell and Systagenix will be poised for future success as a strategically diversified global company, with established commercial scale and a world-class wound care and biologics portfolio.
“The combination of these businesses will form a leading medical technology company with over $2 billion in revenue and a very important position within the healthcare system,” said Buddy Gumina, chairman of the Board of Directors of the parent company of KCI and LifeCell. “The new company, under the proven leadership of Joe Woody, will amplify existing capabilities, open the door for new growth opportunities and improve the lives of patients around the world.”
“Operating as one company will foster collaboration and increased innovation across platforms, leading to exciting new products that will address unmet clinical needs,” said Joe Woody, president & CEO. “The combination of KCI, LifeCell and Systagenix will allow us to strengthen our customer relationships, while creating opportunities to cross-sell our products across the entire continuum of care – following the patient from the operating room to the home with a combined portfolio of best-in-class products and therapies.”
KCI and LifeCell will begin operating as one company immediately under the leadership of President & CEO Joe Woody. Systagenix will be integrated into the combined company upon closing of KCI’s acquisition of Systagenix, which is expected to occur in the fourth quarter of 2013.
About KCI
KCI is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. Headquartered in San Antonio, Texas, KCI is committed to advancing the science of healing and positively impacting patient care by developing customer-driven innovations to meet the evolving needs of healthcare professionals. Proprietary KCI negative pressure technologies have revolutionized the way in which caregivers treat a wide variety of wound types. The V.A.C.® Therapy System has been used on more than 7 million wounds worldwide. Additional information about KCI and its products is available at www.KCI1.com.
About LifeCell
LifeCell Corporation, based in Bridgewater, NJ, is a leader in regenerative medicine, develops and markets innovative tissue repair products for the reconstructive, orthopedic and urogynecologic biosurgery markets. LifeCell™ products include Strattice™ Reconstructive Tissue Matrix and AlloDerm® Regenerative Tissue Matrix for plastic, reconstructive, and general surgical applications; Cymetra® Regenerative Tissue Matrix, a particulate form of AlloDerm® Tissue Matrix suitable for injection; Repliform® Regenerative Tissue Matrix for urogynecologic surgical procedures; Graftjacket® and Conexa™ for orthopedic surgical procedures; and the SPY® Elite System for the visualization and evaluation of tissue perfusion. Additional information about LifeCell and its products is available at www.LifeCell.com.
About Systagenix
Systagenix is a global leader in innovative wound care established in 2008 following the acquisition of Johnson & Johnson’s professional wound care business by One Equity Partners. Systagenix is 100% dedicated to wound care, developing and marketing advanced wound diagnostic and therapeutic solutions and supplying over 20 million advanced wound dressings per month globally. Systagenix’ longstanding commitment to skin and wound care began with innovative wound care treatments developed by the experienced team of R&D Scientists at the Gargrave Centre of Excellence for Wound Healing in North Yorkshire, England. With approximately 800 employees worldwide, Systagenix distributes products and services to more than 100 countries.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130930005524/en/
Contacts
KCI Corporate Communications
Mike Barger, +1-210-255-6824
mike.barger@kci1.com
KCI Investor Relations
Nathan Speicher, +1-210-255-6027
nathan.speicher@kci1.com
Permalink: http://www.me-newswire.net/news/8656/en
Nintedanib* Extended Survival Beyond One Year for Advanced Adenocarcinoma patients After Prior First-Line Chemotherapy
INGELHEIM, Germany - Monday, September 30th 2013 [ME NewsWire]
• In a broad population of lung cancer patients with adenocarcinoma, nintedanib* plus docetaxel provided a significant overall survival benefit, compared to docetaxel alone
• The earlier adenocarcinoma patients failed first-line chemotherapy, the bigger the benefit provided by nintedanib* plus docetaxel
(BUSINESS WIRE) For non U.S. Media Only
New analysis of data from the LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth, provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.1 The results were presented at the European Cancer Congress in Amsterdam.
“Adenocarcinoma is the most common form of non-small cell lung cancer and as the majority of patients with an advanced stage of the disease will ultimately progress after initial therapy, effective second-line treatments are vital,” said Dr. Anders Mellemgaard, Department of Oncology, Herlev University Hospital, Copenhagen. “Recent treatment advances for this sizeable patient population have been limited, but we have reached an important milestone with nintedanib. LUME-Lung 1 showed that nintedanib, when added to chemotherapy, was effective in extending overall survival by 2.3 months for advanced non-small cell lung cancer patients with adenocarcinoma histology and could become an important second-line option for these patients.”
LUME-Lung 1 showed nintedanib* plus docetaxel provided a statistically significant increase in median overall survival from 10.3 months in the placebo arm to 12.6 months in the nintedanib* arm (HR: 0.83, p-value: 0.04).1 In addition, the data demonstrated that the earlier adenocarcinoma patients failed first line chemotherapy, the bigger the benefit that nintedanib* provided.1 Compared to the overall adenocarcinoma patient population, patients with advanced adenocarcinoma who progressed within 9 months after start of their first-line treatment (T<9months) achieved a larger median overall survival benefit of 3 months (10.9 with nintedanib* plus docetaxel vs. 7.9 months with placebo plus docetaxel).1
The analysis of the overall survival benefit observed in adenocarcinoma T<9 months patients suggests T<9months to be a predictive clinical biomarker of nintedanib* benefit in second-line, advanced NSCLC patients with adenocarcinoma histology.1,2
The most common adverse events (AEs) in LUME-Lung 1 were gastrointestinal side effects and reversible liver enzyme elevations which were manageable by supportive treatment or dose reduction (adverse events placebo vs. nintedanib*: nausea 18% vs. 24%, vomiting 9% vs. 17%, diarrhoea 22% vs. 42% and liver enzyme elevation 8% vs. 29%). Withdrawal due to adverse events was similar in both arms, as were Grade 3, bleeding or thromboembolic events.1 The trial results demonstrated that despite the observed adverse events, patients benefited from the additional efficacy of nintedanib*, when added to docetaxel, without significantly further impacting their quality of life.
Boehringer Ingelheim endeavours to make nintedanib* available to patients around the world. Submissions worldwide are currently under preparation.
*Nintedanib is an investigational compound and is not yet approved. Its safety and efficacy has not yet been fully established.
For more information please visit: www.boehringer-ingelheim.com and www.newshome.com
Notes to Editors
Please click on the link below for Notes to Editors
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/30_september_2013oncology.html
References
1 Mellemgaard A, Kaiser R, Douillard J-Y et al. Analysis of overall survival in adenocarcinoma NSCLC patients receiving 2nd line combination treatment with nintedanib (BIBF-1120) + docetaxel in the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled phase 3 study. Oral presentation on 29 September 2013 at 09.00 at The European Cancer Congress 2013 Abstract. no 3409.
2 Kaiser R, Barrueco J, Reck M et al. Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials. Poster presentation on 29 September 2013 at 14.00 at The European Cancer Congress 2013. Abstract no. 3479.
*Nintedanib is an investigational compound and is not yet approved. Its safety and efficacy has not yet been fully established.
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Reinhard Malin
Phone: +49 6132 – 77 90815
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/8657/en
• In a broad population of lung cancer patients with adenocarcinoma, nintedanib* plus docetaxel provided a significant overall survival benefit, compared to docetaxel alone
• The earlier adenocarcinoma patients failed first-line chemotherapy, the bigger the benefit provided by nintedanib* plus docetaxel
(BUSINESS WIRE) For non U.S. Media Only
New analysis of data from the LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth, provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.1 The results were presented at the European Cancer Congress in Amsterdam.
“Adenocarcinoma is the most common form of non-small cell lung cancer and as the majority of patients with an advanced stage of the disease will ultimately progress after initial therapy, effective second-line treatments are vital,” said Dr. Anders Mellemgaard, Department of Oncology, Herlev University Hospital, Copenhagen. “Recent treatment advances for this sizeable patient population have been limited, but we have reached an important milestone with nintedanib. LUME-Lung 1 showed that nintedanib, when added to chemotherapy, was effective in extending overall survival by 2.3 months for advanced non-small cell lung cancer patients with adenocarcinoma histology and could become an important second-line option for these patients.”
LUME-Lung 1 showed nintedanib* plus docetaxel provided a statistically significant increase in median overall survival from 10.3 months in the placebo arm to 12.6 months in the nintedanib* arm (HR: 0.83, p-value: 0.04).1 In addition, the data demonstrated that the earlier adenocarcinoma patients failed first line chemotherapy, the bigger the benefit that nintedanib* provided.1 Compared to the overall adenocarcinoma patient population, patients with advanced adenocarcinoma who progressed within 9 months after start of their first-line treatment (T<9months) achieved a larger median overall survival benefit of 3 months (10.9 with nintedanib* plus docetaxel vs. 7.9 months with placebo plus docetaxel).1
The analysis of the overall survival benefit observed in adenocarcinoma T<9 months patients suggests T<9months to be a predictive clinical biomarker of nintedanib* benefit in second-line, advanced NSCLC patients with adenocarcinoma histology.1,2
The most common adverse events (AEs) in LUME-Lung 1 were gastrointestinal side effects and reversible liver enzyme elevations which were manageable by supportive treatment or dose reduction (adverse events placebo vs. nintedanib*: nausea 18% vs. 24%, vomiting 9% vs. 17%, diarrhoea 22% vs. 42% and liver enzyme elevation 8% vs. 29%). Withdrawal due to adverse events was similar in both arms, as were Grade 3, bleeding or thromboembolic events.1 The trial results demonstrated that despite the observed adverse events, patients benefited from the additional efficacy of nintedanib*, when added to docetaxel, without significantly further impacting their quality of life.
Boehringer Ingelheim endeavours to make nintedanib* available to patients around the world. Submissions worldwide are currently under preparation.
*Nintedanib is an investigational compound and is not yet approved. Its safety and efficacy has not yet been fully established.
For more information please visit: www.boehringer-ingelheim.com and www.newshome.com
Notes to Editors
Please click on the link below for Notes to Editors
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/30_september_2013oncology.html
References
1 Mellemgaard A, Kaiser R, Douillard J-Y et al. Analysis of overall survival in adenocarcinoma NSCLC patients receiving 2nd line combination treatment with nintedanib (BIBF-1120) + docetaxel in the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled phase 3 study. Oral presentation on 29 September 2013 at 09.00 at The European Cancer Congress 2013 Abstract. no 3409.
2 Kaiser R, Barrueco J, Reck M et al. Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials. Poster presentation on 29 September 2013 at 14.00 at The European Cancer Congress 2013. Abstract no. 3479.
*Nintedanib is an investigational compound and is not yet approved. Its safety and efficacy has not yet been fully established.
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Reinhard Malin
Phone: +49 6132 – 77 90815
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
More information
www.boehringer-ingelheim.com
Permalink: http://www.me-newswire.net/news/8657/en
Netsize, the world's leading operator billing platform, achieves PCI DSS certification
ME NewsWire / BusinessWire
New certification enables immediate credit card payments
MEUDON, France - Monday, September 30th 2013
Regulatory News:
Netsize, a Gemalto company, has achieved PCI DSS (Payment Card
Industry & Data Security Scheme) certification, extending the
capabilities of its payment platform beyond operator billing to allow
end user credit card details to be securely stored and thereby
facilitate convenient, immediate transactions. Mobile and digital
content providers will now be able to offer consumers an even wider
range of secure payment options, including higher transaction limits,
to a potential market of two billion consumers and three billion
devices.
The Netsize payment platform already enables content providers to
connect directly to the billing platforms of 160 mobile network
operators in over 50 different countries, supporting seamless and
efficient payments directly from a handset for purchases of apps,
music, images and videos. By meeting the stringent requirements of
the globally recognized PCI DSS standard, Netsize delivers yet more
flexibility to this mobile payment ecosystem, with the same high
standards in security that the company has been known to provide. In
particular, the new certification enables higher transaction limits,
which enables faster time-to-market for a host of premium mobile
services.
New certification enables immediate credit card payments
MEUDON, France - Monday, September 30th 2013
Regulatory News:
Netsize, a Gemalto company, has achieved PCI DSS (Payment Card
Industry & Data Security Scheme) certification, extending the
capabilities of its payment platform beyond operator billing to allow
end user credit card details to be securely stored and thereby
facilitate convenient, immediate transactions. Mobile and digital
content providers will now be able to offer consumers an even wider
range of secure payment options, including higher transaction limits,
to a potential market of two billion consumers and three billion
devices.
The Netsize payment platform already enables content providers to
connect directly to the billing platforms of 160 mobile network
operators in over 50 different countries, supporting seamless and
efficient payments directly from a handset for purchases of apps,
music, images and videos. By meeting the stringent requirements of
the globally recognized PCI DSS standard, Netsize delivers yet more
flexibility to this mobile payment ecosystem, with the same high
standards in security that the company has been known to provide. In
particular, the new certification enables higher transaction limits,
which enables faster time-to-market for a host of premium mobile
services.
Subscribe to:
Posts (Atom)